Controlling hypoxia-inducible factor-2α is critical for maintaining bone homeostasis in mice

Abstract

Pathological bone loss is caused by an imbalance between bone formation and resorption. The bone microenvironments are hypoxic, and hypoxia-inducible factor (HIF) is known to play notable roles in bone remodeling. However, the relevant functions of HIF-2α are not well understood. Here, we have shown that HIF-2α deficiency in mice enhances bone mass through its effects on the differentiation of osteoblasts and osteoclasts. In vitro analyses revealed that HIF-2α inhibits osteoblast differentiation by targeting Twist2 and stimulates RANKL-induced osteoclastogenesis via regulation of Traf6. In addition, HIF-2α appears to contribute to the crosstalk between osteoblasts and osteoclasts by directly targeting RANKL in osteoprogenitor cells. Experiments performed with osteoblast- and osteoclast-specific conditional knockout mice supported a role of HIF-2α in this crosstalk. HIF-2α deficiency alleviated ovariectomy-induced bone loss in mice, and specific inhibition of HIF-2α with ZINC04179524 significantly blocked RANKL-mediated osteoclastogenesis. Collectively, our results suggest that HIF-2α functions as a catabolic regulator in bone remodeling, which is critical for the maintenance of bone homeostasis.

References

[1] Zaidi M. Skeletal remodeling in health and disease. Nat. Med., 2007, 13:791-801

[2] Mellis DJ, Itzstein C, Helfrich MH, Crockett JC. The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. J. Endocrinol., 2011, 211:131-143

[3] Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med., 2005, 11:76-81

[4] Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat. Rev. Genet., 2003, 4:638-649

[5] Seeman E, Delmas PD. Bone quality — the material and structural basis of bone strength and fragility. N. Engl. J. Med., 2006, 354:2250-2261

[6] Ducy P. CBFA1: a molecular switch in osteoblast biology. Dev. Dyn., 2000, 219:461-471

[7] Nakashima K et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell, 2002, 108:17-29

[8] Vignery A. Macrophage fusion: the making of osteoclasts and giant cells. J. Exp. Med., 2005, 202:337-340

[9] Karsenty G, Kronenberg HM, Settembre C. Genetic control of bone formation. Annu. Rev. Cell Dev. Biol., 2009, 25:629-648

[10] Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat. Rev. Rheumatol., 2009, 5:667-676

[11] Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med., 2006, 12:17-25

[12] Zhao C et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab., 2006, 4:111-121

[13] Negishi-Koga T et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat. Med., 2011, 17:1473-1480

[14] Hayashi M et al. Osteoprotection by semaphorin 3A. Nature, 2012, 485:69-74

[15] Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93:165-176

[16] Franzoso G et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev., 1997, 11:3482-3496

[17] Takayanagi H et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature, 2002, 416:744-749

[18] Takayanagi H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell, 2002, 3:889-901

[19] Asagiri M et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med., 2005, 202:1261-1269

[20] Yasuda H et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA, 1998, 95:3597-3602

[21] Schipani E et al. Hypoxia in cartilage: HIF-1α is essential for chondrocyte growth arrest and survival. Genes Dev., 2001, 15:2865-2876

[22] Wang Y et al. The hypoxia-inducible factor α pathway couples angiogenesis to osteogenesis during skeletal development. J. Clin. Investig., 2007, 117:1616-1626

[23] Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J., 2012, 31:2448-2460

[24] Shomento SH et al. Hypoxia-inducible factors 1alpha and 2alpha exert both distinct and overlapping functions in long bone development. J. Cell. Biochem., 2010, 109:196-204

[25] Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res., 2007, 67:4157-4163

[26] Miyauchi Y et al. HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc. Natl Acad. Sci. USA, 2013, 110:16568-16573

[27] Tando T et al. Hif1α is required for osteoclast activation and bone loss in male osteoporosis. Biochem. Biophys. Res. Commun., 2016, 470:391-396

[28] Zhao Q et al. Mice with increased angiogenesis and osteogenesis due to conditional activation of HIF pathway in osteoblasts are protected from ovariectomy induced bone loss. Bone, 2012, 50:763-770

[29] Araldi E, Schipani E. Hypoxia, HIFs and bone development. Bone, 2010, 47:190-196

[30] Araldi E, Khatri R, Giaccia AJ, Simon MC, Schipani E. Lack of HIF-2α in limb bud mesenchyme causes a modest and transient delay of endochondral bone development. Nat. Med., 2011, 17:25-26

[31] Patel SA, Simon MC. Biology of hypoxia-inducible factor-2α in development and disease. Cell Death Differ., 2008, 15:628-634

[32] Ryu Je-Hwang, Chae Chang-Suk, Kwak Ji-Sun, Oh Hwanhee, Shin Youngnim, Huh Yun Hyun, Lee Choong-Gu, Park Yong-Wook, Chun Churl-Hong, Kim Young-Myeong, Im Sin-Hyeog, Chun Jang-Soo. Hypoxia-Inducible Factor-2α Is an Essential Catabolic Regulator of Inflammatory Rheumatoid Arthritis. PLoS Biology, 2014, 12 6 e1001881

[33] Liu, W. et al. GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation. Nat. Commun. 7, 12794 (2016).

[34] Cao JJ, Gregoire BR, Gao H. High-fat diet decreases cancellous bone mass but has no effect on cortical bone mass in the tibia in mice. Bone, 2009, 44:1097-1104

[35] Barreto, R. et al. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7,14470 (2017).

[36] Ott SM. Cortical or trabecular bone: What’s the difference? Am. J. Nephrol., 2018, 47:373-375

[37] Fong GH, Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ., 2008, 15:635-641

[38] Wei J et al. Glucose uptake and runx2 synergize to orchestrate osteoblast differentiation and bone formation. Cell, 2015, 161:1576-1591

[39] Franceschi RT, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J. Cell. Biochem., 2003, 88:446-454

[40] Paredes R et al. Bone-specific transcription factor Runx2 interacts with the 1α,25-dihydroxyvitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells. Mol. Cell. Biol., 2004, 24:8847-8861

[41] Jeong BC et al. The orphan nuclear receptor estrogen receptor-related receptor γ negatively regulates BMP2-induced osteoblast differentiation and bone formation. J. Biol. Chem., 2009, 284:14211-14218

[42] Yoon H et al. NAA10 controls osteoblast differentiation and bone formation as a feedback regulator of Runx2. Nat. Commun., 2014, 5

[43] Yang Der-Chih, Yang Muh-Hwa, Tsai Chih-Chien, Huang Tung-Fu, Chen Yau-Hung, Hung Shih-Chieh. Hypoxia Inhibits Osteogenesis in Human Mesenchymal Stem Cells through Direct Regulation of RUNX2 by TWIST. PLoS ONE, 2011, 6 9 e23965

[44] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423:337-342

[45] Lomaga MA et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev., 1999, 13:1015-1024

[46] Naito A et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells, 1999, 4:353-362

[47] Kronenberg HM. Twist genes regulate Runx2 and bone formation. Dev. Cell., 2004, 6:317-318

[48] Wu C et al. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev., 2015, 29:817-831

[49] Kanemoto S et al. Luman is involved in osteoclastogenesis through the regulation of DC-STAMP expression, stability and localization. J. Cell Sci., 2015, 128:4353-4365

[50] Gohda J et al. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J., 2005, 24:790-799

[51] Sun H et al. TRAF6 upregulates expression of HIF-1α and promotes tumor angiogenesis. Cancer Res., 2013, 73:4950-4959

[52] Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer, 2002, 2:673-682

[53] Arnett TR et al. Hypoxia is a major stimulator of osteoclast formation and bone resorption. J. Cell. Physiol., 2003, 196:2-8

[54] Lin YH et al. Osteosarcoma: molecular pathogenesis and iPSC modeling. Trends Mol. Med., 2017, 23:737-755

[55] Maxwell PH et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999, 399:271-275

[56] Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol., 2003, 23:9361-9374

[57] Raval RR et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol., 2005, 25:5675-5686

[58] Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells. Cancer Res., 2005, 65:3299-3306

[59] Saito T et al. Transcriptional regulation of endochondral ossification by HIF-2α during skeletal growth and osteoarthritis development. Nat. Med., 2010, 16:678-686

[60] Yang S et al. Hypoxia-inducible factor-2α is a catabolic regulator of osteoarthritic cartilage destruction. Nat. Med., 2010, 16:687-693

[61] Ryu JH et al. Interleukin-6 plays an essential role in hypoxia-inducible factor 2α–induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum., 2011, 63:2732-2743

[62] Ryu JH et al. Hypoxia-inducible factor-2α regulates Fas-mediated chondrocyte apoptosis during osteoarthritic cartilage destruction. Cell Death Differ., 2012, 19:440-450

[63] Zhou J, Brüne B. Cytokines and hormones in the regulation of hypoxia inducible factor-1alpha (HIF-1alpha). Cardiovasc. Hematol. Agents Med. Chem., 2006, 4:189-197

[64] Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Investig., 2006, 116:1186-1194

[65] Eastell R, Walsh JS, Watts NB, Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone, 2011, 49:82-88

[66] Kennel KA, Drake MT. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin. Proc., 2009, 84:632-638

[67] Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J. Clin. Endocrinol. Metab., 2012, 97:311-325

[68] Lim KE et al. Core binding factor β of osteoblasts maintains cortical bone mass via stabilization of Runx2 in mice. J. Bone Miner. Res., 2015, 30:715-722

[69] Li J et al. Inhibition of osteoclastogenesis and bone resorption in vitro and in vivo by a prenylflavonoid xanthohumol from hops. Sci. Rep., 2015, 5

Funding

National Research Foundation of Korea (NRF)(NRF-2015R1D1A1A01057870)

Korea Health Industry Development Institute (KHIDI)(HI16C0287)